Rosuvastatin and Renal Endothelial Function

Inclusion Criteria: * Female and male patients aged between 18 and 75 years * fasting LDL C concentrations \>=160 and \< 250mg/dl * fasting TG concentrations =\< 350mg/dl Exclusion Criteria: * History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins). * History of hypersensitivity reaction to inulin. * Lipid-lowering drugs (including lipid lowering dietary supplements of food additives) within the last 4 weeks. * Diabetes mellitus, defined as glycosylated hemoglobin (HbA1C) above the upper limit of normal (ULN). * Uncontrolled arterial hypertension (\>160/100mm Hg). * Subjects considered to be unstable (event within 12 weeks) by the investigator after the following events: a myocardial infarction, unstable angina, myocardial revascularisation (PTCA, CABG surgery or another revascularisation procedure) or a transient ischaemic attack (TIA) or stroke. * Significant arrythmias or conduction disturbances. * Congestive heart failure (NYHA classes III or IV). * Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have positive serum pregnancy test (a serum beta-human chorionic gonadotropin analysis). * History of homozygous familial hypercholesterolaemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia). * Use of concomitant medications. * Current active liver disease(SGPT \> 2xULN) or severe hepatic impairment. * Unexplained serum CK \> 3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise etc.). * Serum creatinine \> 2,0 mg/dl and creatinine clearance \<80ml/min. * History of nephrolithiasis with calcium oxalate aggregation. * Uncontrolled hypothyroidism defined as a thyroid stimulating hormone (TSH) \> 1,5 times the UL or subjects whose thyroid replacement therapy was initiated within the last 3 month. * Severe disorders of the gastrointestinal tract or other diseases which interfere with the pharmacodynamics and pharmacokinetics of the study drug. * History of malignancy(unless a documented disease-free period exceeding 10 years is present) with the exception of basal cell or squamous cell carcinoma of the skin. Women with a history of cervical dysplasia would be permitted to enter the study provided they have 3 consecutive clear Papanicolaou (Pap) smears. * History of organ allografts. * Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subjects´s safety or successful participation in the trial. * Participation in a clinical study within 4 weeks preceding treatment start. * Past or present alcohol or drug abuse. * Suspected or confirmed poor compliance. * Previous enrolment in this study.